These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1338 related items for PubMed ID: 17127481

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S.
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [Abstract] [Full Text] [Related]

  • 23. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ.
    Semin Thromb Hemost; 1997 Jul; 23(4):371-7. PubMed ID: 9263354
    [Abstract] [Full Text] [Related]

  • 24. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
    Cucuianu A, Stoia M, Farcaş A, Dima D, Zdrenghea M, Paţiu M, Olinic D, Petrov L.
    Rom J Intern Med; 2006 Jul; 44(4):397-406. PubMed ID: 18386616
    [Abstract] [Full Text] [Related]

  • 25. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
    Panova-Noeva M, Marchetti M, Russo L, Tartari CJ, Leuzzi A, Finazzi G, Rambaldi A, ten Cate H, Falanga A.
    Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
    [Abstract] [Full Text] [Related]

  • 26. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
    Das S, Karachiwala H, Cherian SV, Garcha AS, Jasti S, Gajra A.
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E.
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
    Landolfi R, Patrono C.
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R, Cipriani MC, Novarese L.
    Best Pract Res Clin Haematol; 2006 Sep; 19(3):617-33. PubMed ID: 16781491
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.